Cargando…

Small molecule targeted NIR dye conjugate for imaging LHRH receptor positive cancers

Overexpression of Luteinizing Hormone Releasing Hormone Receptor (LHRH-R) in various cancers and restricted expression of the receptor in healthy cells qualifies it as a valuable cancer biomarker. Previously, LHRH-R targeted peptides have been utilized to deliver attached payloads to LHRH-R expressi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roy, Jyoti, Kaake, Miranda, Low, Philip S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349437/ https://www.ncbi.nlm.nih.gov/pubmed/30719210 http://dx.doi.org/10.18632/oncotarget.26520

Ejemplares similares

Design and validation of fibroblast activation protein alpha targeted imaging and therapeutic agents
por: Roy, Jyoti, et al.
Publicado: (2020)

(99m)Tc-LHRH in tumor receptor imaging
por: Hao, Dawei, et al.
Publicado: (2017)

Synthesis of Radiolabeled Technetium- and Rhenium-Luteinizing Hormone-Releasing Hormone ((99m)Tc/Re-Acdien-LHRH) Conjugates for Targeted Detection of Breast Cancer Cells Overexpressing the LHRH Receptor
por: Calderon, Lindsay E., et al.
Publicado: (2021)

Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125
por: Seitz, Stephan, et al.
Publicado: (2014)

Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors
por: Curtis, Kelly K., et al.
Publicado: (2014)

LHRH analogues and breast cancer.
por: Korkut, E., et al.
Publicado: (1991)

Recent advances in small molecule dye-based nanotheranostics for NIR-II photoacoustic imaging-guided cancer therapy
por: Zhou, Wen, et al.
Publicado: (2022)

Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer
por: Szabó, Zsuzsanna, et al.
Publicado: (2021)

LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer
por: Obayemi, J. D., et al.
Publicado: (2020)

Improving ovarian cancer imaging with LHRH-NBs: an experimental study
por: Li, Wenjuan, et al.
Publicado: (2016)

Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer
por: Visapää, Harri
Publicado: (2017)

LHRH agonists and the prevention of breast and ovarian cancer.
por: Pike, M. C., et al.
Publicado: (1989)

TAT-LHRH conjugated low molecular weight chitosan as a gene carrier specific for hepatocellular carcinoma cells
por: Liu, Lanxia, et al.
Publicado: (2014)

Oligomerization Strategy of D-A-Type Conjugated Molecules for Improved NIR-II Fluorescence Imaging
por: Zou, Tongqing, et al.
Publicado: (2023)

Androgen-Receptor Positive Lacrimal Sac Adenocarcinoma Demonstrating Long-Lasting Response to LHRH Analog Plus Abiraterone Treatment
por: Vagia, Elena, et al.
Publicado: (2015)

Shrinkage of uterine fibroids by preoperative LHRH analogue injection.
por: McClelland, H. R., et al.
Publicado: (1992)

Selective Tumor Targeting of Desacetyl Vinblastine Hydrazide and Tubulysin B via Conjugation to a Cholecystokinin 2 Receptor (CCK2R) Ligand
por: Wayua, Charity, et al.
Publicado: (2015)

Antitumor Activity and Mechanism of Action of Hormonotoxin, an LHRH Analog Conjugated to Dermaseptin-B2, a Multifunctional Antimicrobial Peptide
por: Couty, Mickael, et al.
Publicado: (2021)

Enhanced Anti-Tumoral Activity of Methotrexate-Human Serum Albumin Conjugated Nanoparticles by Targeting with Luteinizing Hormone-Releasing Hormone (LHRH) Peptide
por: Taheri, Azade, et al.
Publicado: (2011)

Small Molecule NIR‐II Dyes for Switchable Photoluminescence via Host –Guest Complexation and Supramolecular Assembly with Carbon Dots
por: Sar, Dinabandhu, et al.
Publicado: (2022)

Visible-to-NIR-Light Activated Release: From Small Molecules to Nanomaterials
por: Weinstain, Roy, et al.
Publicado: (2020)

Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5)
por: Emons, Günter, et al.
Publicado: (2014)

Effect of Extending the Conjugation of Dye Molecules on the Efficiency and Stability of Dye-Sensitized Solar Cells
por: Zhou, Pengjuan, et al.
Publicado: (2021)

Combination of changeable π-conjugation and hydrophilic groups for developing water-soluble small-molecule NIR-II fluorogenic probes
por: Zhang, Xiaofan, et al.
Publicado: (2023)

PDMS composites with photostable NIR dyes for multi-modal ultrasound imaging
por: Lewis-Thompson, India, et al.
Publicado: (2022)

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma
por: Treszl, Andrea, et al.
Publicado: (2013)

LHRH analogues in breast cancer: clever, but do we need them?
por: Smith, I. E.
Publicado: (1991)

Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules
por: Hawner, Manuel, et al.
Publicado: (2020)

Quasi-dendritic sulfonate-based organic small molecule for high-quality NIR-II bone-targeted imaging
por: Chen, Pengfei, et al.
Publicado: (2023)

Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes
por: He, Yingna, et al.
Publicado: (2010)

Gender Disparity Impacts on Thymus Aging and LHRH Receptor Antagonist-Induced Thymic Reconstitution Following Chemotherapeutic Damage
por: Hun, Michael Ly, et al.
Publicado: (2020)

Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer
por: Ndinguri, Margaret, et al.
Publicado: (2023)

Novel bright-emission small-molecule NIR-II fluorophores for in vivo tumor imaging and image-guided surgery
por: Sun, Yao, et al.
Publicado: (2017)

Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture
por: Wilson, Hannah C.P., et al.
Publicado: (2015)

Subclinical leprosy manifesting as a reversal reaction after LHRH agonist administration
por: Carmo, R.L.M.L., et al.
Publicado: (2018)

Bifacial Dye-Sensitized Solar Cells Utilizing Visible and NIR Dyes: Implications of Dye Adsorption Behaviour
por: Shaban, Suraya, et al.
Publicado: (2023)

Tandem Dye-Doped Nanoparticles for NIR Imaging via Cerenkov Resonance Energy Transfer
por: Genovese, Damiano, et al.
Publicado: (2020)

J-aggregates of meso-[2.2]paracyclophanyl-BODIPY dye for NIR-II imaging
por: Li, Kang, et al.
Publicado: (2021)

Small Molecule NIR‐II Dyes for Switchable Photoluminescence via Host –Guest Complexation and Supramolecular Assembly with Carbon Dots (Adv. Sci. 22/2022)
por: Sar, Dinabandhu, et al.
Publicado: (2022)

Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.
por: Philip, P. A., et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_f30vfd0avil4map7726m8em7u1